|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5786158A
(en)
|
1992-04-30 |
1998-07-28 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1117778A2
(en)
|
1998-10-02 |
2001-07-25 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
|
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
CN1331214A
(zh)
*
|
2000-06-30 |
2002-01-16 |
上海博德基因开发有限公司 |
一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
|
|
WO2002059285A1
(en)
|
2000-10-27 |
2002-08-01 |
Fred Hutchinson Cancer Research Center |
Methods for immortalizing cells
|
|
CN1376686A
(zh)
*
|
2001-03-22 |
2002-10-30 |
上海博德基因开发有限公司 |
一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20030148954A1
(en)
|
2001-11-02 |
2003-08-07 |
Wisconsin Alumni Research Foundation |
Agents and methods for modulating activator protein-1-mediated cellular processes
|
|
EP1448599A2
(en)
|
2001-11-14 |
2004-08-25 |
Lorantis Limited |
Inhibitors of the notch signalling pathway for use in the treatment of cancer
|
|
PL373256A1
(en)
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
|
WO2004009617A1
(ja)
|
2002-07-18 |
2004-01-29 |
Osaka Industrial Promotion Organization |
Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
|
|
SI2263692T1
(sl)
|
2002-12-24 |
2020-10-30 |
Rinat Neuroscience Corp. |
Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
|
|
AU2004294563B2
(en)
|
2003-11-26 |
2009-03-26 |
Health Research, Inc. |
Use of notch pathway interfering agents for treatment of plasma cell disorders
|
|
WO2006001956A2
(en)
|
2004-05-20 |
2006-01-05 |
The Board Of Trustees Of The University Of Illinois |
Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
|
|
US20070077245A1
(en)
|
2004-08-04 |
2007-04-05 |
The Brigham And Women's Hospital, Inc. |
NOTCH mutations leading to increased receptor signaling
|
|
WO2006053063A2
(en)
|
2004-11-05 |
2006-05-18 |
The Regents Of The University Of California |
Notch-1 assay to detect neurodegenerative diseases
|
|
AU2005302846A1
(en)
*
|
2004-11-10 |
2006-05-18 |
Hubrecht Laboratorium |
Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
|
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
CA2600908A1
(en)
|
2005-03-04 |
2006-09-08 |
The Hospital For Sick Children |
Methods for cancer prognosis
|
|
US20070072222A1
(en)
|
2005-09-23 |
2007-03-29 |
Franziska Boess |
FABP4 as biomarker for toxic effect
|
|
WO2007061988A2
(en)
|
2005-11-22 |
2007-05-31 |
University Of Vermont And State Agricultural College |
Methods for determining notch signaling and uses thereof
|
|
WO2008057144A2
(en)
|
2006-05-15 |
2008-05-15 |
The Brigham And Women's Hospital, Inc. |
Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
|
|
EP2032166B1
(en)
|
2006-06-13 |
2013-04-10 |
OncoMed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
CN101605815B
(zh)
*
|
2006-12-18 |
2013-11-13 |
健泰科生物技术公司 |
拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
|
|
JP2010520280A
(ja)
|
2007-03-05 |
2010-06-10 |
ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム |
ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
|
|
PE20090321A1
(es)
*
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
US8119366B2
(en)
|
2007-10-05 |
2012-02-21 |
Trojan Technologies, Ltd. |
Antennapedia-dominant negative mastermind-like construct
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
PT2307051E
(pt)
|
2008-07-08 |
2015-05-21 |
Oncomed Pharm Inc |
Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos
|
|
US20110286916A1
(en)
*
|
2008-11-20 |
2011-11-24 |
Jose Miguel Aste-Amezaga |
Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
|
|
EP2443151A1
(en)
|
2009-06-18 |
2012-04-25 |
Pfizer Inc. |
Anti notch-1 antibodies
|
|
MA33973B1
(fr)
|
2009-09-30 |
2013-02-01 |
Genentech Inc |
Méthodes de traitement du cancer à l'aide d'antagonistes de notch
|
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
WO2012080891A1
(en)
|
2010-12-15 |
2012-06-21 |
Rinat Neuroscience Corp. |
Anti-notch-1 antibodies
|
|
JP6016800B2
(ja)
|
2010-12-15 |
2016-10-26 |
ワイス・エルエルシー |
抗ノッチ１抗体
|